{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:21:28Z","timestamp":1793665288415,"version":"4.5.1"},"reference-count":105,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Extracorporeal membrane oxygenation (ECMO) is a continuously evolving and increasingly utilized life-support therapy. ECMO requires systemic anticoagulation, which exposes patients to an increased risk of heparin-induced thrombocytopenia (HIT). Clinical experience with alternative anticoagulants in this setting remains limited. The 2022 Extracorporeal Life Support Organization (ELSO)\u2014Anticoagulation Guidelines provide no specific recommendations regarding anticoagulant selection for ECMO patients with HIT. This article aims to review current practices, available evidence, and most recent advances concerning the use of alternative anticoagulants in ECMO patients with HIT. In patients with a high suspicion or confirmed diagnosis of HIT, management includes discontinuing all forms of heparin exposure and initiating an alternative anticoagulant, such as a direct thrombin inhibitor and\/or factor Xa inhibitor. Direct thrombin inhibitors act independently of antithrombin and have a short half-life, providing a more consistent and predictable anticoagulation effect. Most available data, primarily from retrospective studies, describe the use of argatroban in ECMO patients with HIT. Bivalirudin has also been used as an alternative anticoagulant in this population, with no significant increase in bleeding or thrombotic complications. However, the current evidence remains limited to small, retrospective, single-center or case\u2013control studies. Fondaparinux has shown effectiveness in the HIT setting and appears to have a low risk of complications. Factor XIIa inhibitors represent a novel class of anticoagulants currently under investigation, evaluated only in animal models. Growing clinical experience with alternative anticoagulants, particularly direct thrombin inhibitors, suggests that their use will likely become a primary focus in ECMO anticoagulation management in the coming years.<\/jats:p>","DOI":"10.3390\/biomedicines13112705","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:11:16Z","timestamp":1762254676000},"page":"2705","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Alternative Anticoagulation for Patients with Heparin-Induced Thrombocytopenia on ECMO: A Narrative Review"],"prefix":"10.3390","volume":"13","author":[{"given":"Dragana","family":"Unic-Stojanovic","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"},{"name":"Institute for Cardiovascular Diseases Dedinje, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar","family":"Vukovic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"},{"name":"Institute for Cardiovascular Diseases Dedinje, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5110-7102","authenticated-orcid":false,"given":"Ivan","family":"Ilic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"},{"name":"Institute for Cardiovascular Diseases Dedinje, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica Miljkovic","family":"Stojicic","sequence":"additional","affiliation":[{"name":"Institute for Cardiovascular Diseases Dedinje, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slobodan","family":"Tanaskovic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"},{"name":"Institute for Cardiovascular Diseases Dedinje, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolina","family":"Kangrga","sequence":"additional","affiliation":[{"name":"Institute for Cardiovascular Diseases Dedinje, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6193-3662","authenticated-orcid":false,"given":"Sasa","family":"Rajsic","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia and Intensive Care Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rajsic, S., Breitkopf Jadzic, D., Popovic Krneta, M., Tauber, H., and Treml, B. (2022). Anticoagulation strategies during extracorporeal membrane oxygenation: A narrative review. J. Clin. Med., 11.","DOI":"10.3390\/jcm11175147"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1186\/s13054-016-1570-4","article-title":"The inflammatory response to extracorporeal membrane oxygenation (ECMO): A review of the pathophysiology","volume":"20","author":"Millar","year":"2016","journal-title":"Crit. Care"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13613-022-01067-9","article-title":"Extracorporeal membrane oxygenation for cardiogenic shock: A meta-analysis of mortality and complications","volume":"12","author":"Rajsic","year":"2022","journal-title":"Ann. Intensive Care"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/MAT.0000000000000150","article-title":"Extracorporeal life support: Experience with 2,000 patients","volume":"61","author":"Gray","year":"2015","journal-title":"ASAIO J."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Rajsic, S., Breitkopf, R., Oezpeker, U.C., Bukumiri\u0107, Z., Dobesberger, M., and Treml, B. (2022). The role of excessive anticoagulation and missing hyperinflammation in ECMO-associated bleeding. J. Clin. Med., 11.","DOI":"10.3390\/jcm11092314"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13613-016-0196-7","article-title":"Predictive factors of bleeding events in adults undergoing extracorporeal membrane oxygenation","volume":"6","author":"Aubron","year":"2016","journal-title":"Ann. Intensive Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.athoracsur.2020.02.012","article-title":"Risk factors of bleeding in patients undergoing venoarterial extracorporeal membrane oxygenation","volume":"111","author":"Ellouze","year":"2021","journal-title":"Ann. Thorac. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/MAT.0000000000001510","article-title":"ELSO Interim Guidelines for Venoarterial Extracorporeal Membrane Oxygenation in Adult Cardiac Patients","volume":"67","author":"Lorusso","year":"2021","journal-title":"ASAIO J."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ghiselli, G. (2019). Heparin Binding Proteins as Therapeutic Target: An historical account and current trends. Medicine, 6.","DOI":"10.3390\/medicines6030080"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0950-3536(05)80017-4","article-title":"Pharmacokinetics of heparin and low molecular weight heparin","volume":"3","author":"Boneu","year":"1990","journal-title":"Bailliere\u2019s Clin. Haematol."},{"key":"ref_11","first-page":"1015","article-title":"Revisiting the pharmacology of unfractionated heparin","volume":"58","author":"Derbalah","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MAT.0000000000001652","article-title":"2021 ELSO Adult and Pediatric Anticoagulation Guidelines","volume":"68","author":"McMichael","year":"2022","journal-title":"ASAIO J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1007\/s00134-018-5346-y","article-title":"Prevalence and outcome of heparin-induced thrombocytopenia diagnosed under veno-arterial extracorporeal membrane oxygenation: A retrospective nationwide study","volume":"44","author":"Kimmoun","year":"2018","journal-title":"Intensive Care Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e1031","DOI":"10.1097\/CCM.0000000000001869","article-title":"Platelet count trends and prevalence of heparin- induced thrombocytopenia in a cohort of extracorporeal membrane oxygenator patients","volume":"44","author":"Sokolovic","year":"2016","journal-title":"Crit. Care Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMcp1411910","article-title":"Clinical practice. Heparin-Induced Thrombocytopenia","volume":"373","author":"Greinacher","year":"2015","journal-title":"New Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"L\u00fcsebrink, E., Scherer, C., Binzenh\u00f6fer, L., Hoffmann, S., H\u00f6pler, J., Kellnar, A., Thienel, M., Joskowiak, D., Peter\u00df, S., and Petzold, T. (2023). Heparin-induced thrombocytopenia in patients undergoing venoarterial extracorporeal membrane oxygenation. J. Clin. Med., 12.","DOI":"10.3390\/jcm12010362"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ng, J.Y., D\u2019Souza, M., Hutani, F., and Choi, P. (2024). Management of heparin-induced thrombocytopenia: A contemporary review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13164686"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/17474086.2021.1905512","article-title":"Heparin-induced thrombocytopenia: Pathophysiology, diagnosis and treatment","volume":"14","author":"Hvas","year":"2021","journal-title":"Expert. Rev. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1055\/s-0039-1688827","article-title":"Frequency and Clinical Impact of Platelet Factor 4-Specific Antibodies in Patients Undergoing Extracorporeal Membrane Oxygenation","volume":"119","author":"Vayne","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.21037\/acs.2018.12.02","article-title":"Heparin-induced thrombocytopenia during extracorporeal life support: Incidence, management and outcomes","volume":"8","author":"Choi","year":"2019","journal-title":"Ann. Cardiothorac. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.jcrc.2015.07.030","article-title":"Clinically suspected heparin-induced thrombocytopenia during extracorporeal membrane oxygenation","volume":"30","author":"Glick","year":"2015","journal-title":"J. Crit. Care"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.athoracsur.2008.10.060","article-title":"Heparin-induced thrombocytopenia in patients with ventricular assist devices: Are new prevention strategies required?","volume":"87","author":"Warkentin","year":"2009","journal-title":"Ann. Thorac. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1051\/ject\/201143005","article-title":"Heparin-induced thrombocytopenia and extracorporeal membrane oxygenation: A case report and review of the literature","volume":"43","author":"Pollak","year":"2011","journal-title":"J. Extra Corpor. Technol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/j.jacc.2016.02.073","article-title":"Heparin-induced thrombocytopenia: A comprehensive clinical review","volume":"67","author":"Salter","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00134-020-06031-4","article-title":"Platelets and extracorporeal membrane oxygenation in adult patients: A systematic review and meta-analysis","volume":"46","author":"Jiritano","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11239-021-02546-9","article-title":"Heparin-induced thrombocytopenia in extra-corporeal membrane oxygenation: Epidemiology, outcomes, and diagnostic challenges","volume":"53","author":"Zaaqoq","year":"2022","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1097\/CCM.0000000000004261","article-title":"Frequency of thrombocytopenia and heparin-induced thrombocytopenia in patients receiving extracorporeal membrane oxygenation compared with cardiopulmonary bypass and the limited sensitivity of pretest probability score","volume":"48","author":"Arachchillage","year":"2020","journal-title":"Crit. Care Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1177\/0267659119842056","article-title":"Heparin-induced thrombocytopenia in patients on extracorporeal membrane oxygenation and the role of a heparin-bonded circuit","volume":"34","author":"Pabst","year":"2019","journal-title":"Perfusion"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/asheducation-2013.1.668","article-title":"Heparin-induced thrombocytopenia","volume":"2013","author":"Lee","year":"2013","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjh.19180","article-title":"Diagnosis and management of heparin-induced thrombocytopenia: Third edition","volume":"204","author":"Arachchillage","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1053\/j.jvca.2022.02.030","article-title":"The predictive value of the 4Ts and HEP score at recommended cutoffs in patients with mechanical circulatory support devices","volume":"36","author":"Kram","year":"2022","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/j.1538-7836.2004.00949.x","article-title":"Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass","volume":"2","author":"Boutouyrie","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1053\/j.jvca.2022.03.043","article-title":"Heparin-Induced Thrombocytopenia in Patients With Mechanical Circulatory Support","volume":"36","author":"Bolliger","year":"2022","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/0267659119881266","article-title":"Predictive value of scoring tools in determining heparin-induced thrombocytopenia in patients on extracorporeal membrane oxygenation","volume":"35","author":"Sullivan","year":"2020","journal-title":"Perfusion"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/ijlh.12993","article-title":"Laboratory diagnosis of heparin-induced thrombocytopenia","volume":"41","author":"Warkentin","year":"2019","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1097\/CCM.0000000000004090","article-title":"Evaluation of serotonin release assay and enzyme-linked immunosorbent assay optical density thresholds for heparin-induced thrombocytopenia in patients on extracorporeal membrane oxygenation","volume":"48","author":"Kataria","year":"2020","journal-title":"Crit. Care Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.thromres.2016.01.025","article-title":"Assessing the clinical and cost impact of on-demand immunoassay testing for the diagnosis of heparin induced thrombocytopenia","volume":"140","author":"Caton","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1111\/jth.14575","article-title":"Heparin-induced thrombocytopenia complicating extracorporeal membrane oxygenation support: Review of the literature and alternative anticoagulants","volume":"17","author":"Pollak","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1111\/j.1538-7836.2010.04059.x","article-title":"The HIT expert probability (HEP) score: A novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion","volume":"8","author":"Cuker","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: Heparin-induced thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e495S","DOI":"10.1378\/chest.11-2303","article-title":"Treatment and prevention of heparin-induced thrombocytopenia","volume":"141","author":"Linkins","year":"2012","journal-title":"Chest"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40560-017-0235-y","article-title":"Argatroban for an alternative anticoagulant in HIT during ECMO","volume":"5","author":"Pelen","year":"2017","journal-title":"J. Intensive Care"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1525-1594.2007.00388.x","article-title":"Argatroban in extracorporeal membrane oxygenation","volume":"31","author":"Beiderlinden","year":"2007","journal-title":"Artif. Organs"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1053\/j.jvca.2025.05.040","article-title":"Anticoagulation monitoring during extracorporeal membrane oxygenation: A narrative review","volume":"39","author":"Rajsic","year":"2025","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_45","first-page":"w20210","article-title":"Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland","volume":"150","author":"Alberio","year":"2020","journal-title":"Swiss Med. Wkly."},{"key":"ref_46","first-page":"291","article-title":"Diagnosis and management of heparin-induced thrombocytopenia","volume":"39","author":"Gruel","year":"2020","journal-title":"Anaesth. Crit. Care Pain. Med."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Lubnow, M., Berger, J., Schneckenpointner, R., Zeman, F., Lunz, D., Philipp, A., Foltan, M., Lehle, K., Heimerl, S., and Hart, C. (2022). Prevalence and outcomes of patients developing heparin-induced thrombocytopenia during extracorporeal membrane oxygenation. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0272577"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/bjh.17870","article-title":"Impact of major bleeding and thrombosis on 180-day survival in patients with severe COVID-19 supported with veno-venous extracorporeal membrane oxygenation in the United Kingdom: A multicentre observational study","volume":"196","author":"Arachchillage","year":"2022","journal-title":"Br. Soc. Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1051\/ject\/201749115","article-title":"Argatroban for Heparin-Induced Thrombocytopenia during Venovenous Extracorporeal Membrane Oxygenation with Continuous Venovenous Hemofiltration","volume":"49","author":"Sin","year":"2017","journal-title":"J. Extracorpor. Technol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13054-021-03581-x","article-title":"Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: A propensity-score matched study","volume":"25","author":"Fisser","year":"2021","journal-title":"Crit. Care"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/01.CIR.103.14.1838","article-title":"ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin- induced thrombocytopenia","volume":"103","author":"Lewis","year":"2001","journal-title":"Circulation"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1097\/MAT.0000000000001733","article-title":"Injection of recombinant tissue plasminogen activator into extracorporeal membrane oxygenators postpones oxygenator exchange in COVID-19","volume":"68","author":"Mang","year":"2022","journal-title":"ASAIO J."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Zhong, H., Zhu, M.L., Yu, Y.T., Li, W., Xing, S.P., Zhao, X.Y., Wang, W.J., Gu, Z.C., and Gao, Y. (2020). Management of bivalirudin anticoagulation therapy for extracorporeal membrane oxygenation in heparin-induced thrombocytopenia: A case report and a systematic review. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.565013"},{"key":"ref_54","first-page":"27F","article-title":"The mechanism of action of thrombin inhibitors","volume":"12","author":"Bates","year":"2000","journal-title":"J. Invasive Cardiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1067\/mcp.2002.124522","article-title":"Bivalirudin pharmacokinetics and pharmacodynamics: Effect of renal function, dose, and gender","volume":"71","author":"Robson","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Navaei, A., Kostousov, V., and Teruya, J. (2023). Is it time to switch to bivalirudin for ECMO anticoagulation?. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1237601"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1051\/ject\/201850161","article-title":"Bivalirudin anticoagulation dosing protocol for extracorporeal membrane oxygenation: A retrospective review","volume":"50","author":"Netley","year":"2018","journal-title":"J. Extracorpor. Technol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jtha.2022.11.014","article-title":"Anticoagulation in adult patients supported with extracorporeal membrane oxygenation: Guidance from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis","volume":"21","author":"Helms","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/00185787231188924","article-title":"Evaluation of Bivalirudin During Adult Extracorporeal Membrane Oxygenation: A Retrospective Characterization of Dosing, Efficacy and Bleeding","volume":"59","author":"Lopez","year":"2024","journal-title":"Hosp. Pharm."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/MAT.0000000000000691","article-title":"Evaluation of systemic heparin versus bivalirudin in adult patients supported by extracorporeal membrane oxy- genation","volume":"64","author":"Berei","year":"2018","journal-title":"ASAIO J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"R275","DOI":"10.1186\/cc10556","article-title":"Bivalirudin-based versus conventional heparin anticoagulation for postcardi- otomy extracorporeal membrane oxygenation","volume":"15","author":"Ranucci","year":"2011","journal-title":"Crit. Care"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1177\/03913988221106225","article-title":"Evaluation of anticoagulation with bivalirudin for heparin-induced thrombocytopenia during extracorporeal membrane oxygenation","volume":"45","author":"Hanna","year":"2022","journal-title":"Int. J. Artif. Organs"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/PHAR.1016","article-title":"Comparison of bivalirudin dosing strategies using total, adjusted, and ideal body weights in obese patients with heparin-induced thrombocytopenia","volume":"32","author":"Tsu","year":"2012","journal-title":"Pharmacotherapy"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/jocs.14458","article-title":"Heparin vs bivalirudin anticoagulation for extracorporeal membrane oxygenation","volume":"35","author":"Kaseer","year":"2020","journal-title":"J. Card. Surg."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/MAT.0000000000001814","article-title":"Comparison of bivalirudin versus heparin for anticoagulation during extracorporeal membrane oxygenation","volume":"69","author":"Hasegawa","year":"2023","journal-title":"ASAIO J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/PCC.0000000000002384","article-title":"Evaluation of bivalirudin as an alternative to heparin for systemic anticoagulation in pediatric extracorporeal membrane oxygenation","volume":"21","author":"Hamzah","year":"2020","journal-title":"Pediatr. Crit. Care Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.thromres.2020.04.009","article-title":"A comparison of bivalirudin and heparin for patients on extracorporeal membrane oxygenation","volume":"190","author":"Brown","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Ma, M., Liang, S., Zhu, J., Dai, M., Jia, Z., Huang, H., and He, Y. (2022). The efficacy and safety of bivalirudin versus heparin in the anticoagulation therapy of extracorporeal membrane oxygenation: A systematic review and meta-analysis. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.771563"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/CCM.0000000000004944","article-title":"Comparison of anticoagulation strategies in patients requiring venovenous extracorporeal membrane oxygenation: Heparin versus bivalirudin","volume":"49","author":"Rivosecchi","year":"2021","journal-title":"Crit. Care Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/cc11314","article-title":"Bivalirudin and post-cardiotomy ECMO: A word of caution","volume":"16","author":"Ranucci","year":"2012","journal-title":"Crit. Care"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1177\/0267659120965104","article-title":"Platelet factor-4 concentration in adult veno-arterial ECMO patients","volume":"36","author":"Mazzeffi","year":"2021","journal-title":"Perfusion"},{"key":"ref_72","first-page":"e0485","article-title":"Extracorporeal membrane oxygenation complications in heparin- and bivalirudin-treated patients","volume":"3","author":"Giuliano","year":"2021","journal-title":"Crit. Care Explor."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2125.2011.03916.x","article-title":"Direct thrombin inhibitors","volume":"72","author":"Lee","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1345\/aph.1D436","article-title":"Lepirudin in heparin-induced thrombocytopenia and extracorporeal membranous oxygenation","volume":"38","author":"Dager","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMct1206642","article-title":"Nonheparin anticoagulants for heparin-induced thrombocytopenia","volume":"368","author":"Kelton","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Yin, Q., Han, L., Wang, Y., Kang, F., Cai, F., Wu, L., Zheng, X., Li, L., Dong, L.E., and Dong, L. (2024). Unlocking the potential of fondaparinux: Guideline for optimal usage and clinical suggestions (2023). Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1352982"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"344","DOI":"10.5301\/ijao.5000302","article-title":"Successful use of fondaparinux in a patient with heparin-induced thrombocytopenia while on extracorporeal membrane oxygenation after mitral valve redo surgery","volume":"37","author":"Parlar","year":"2014","journal-title":"Int. J. Artif. Organs"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.htct.2020.05.008","article-title":"Fondaparinux for systemic anticoagulation during continuous hemofiltration in a patient with heparin-induced thrombocytopenia and limb ischemia\u2014A case report","volume":"44","author":"Osawa","year":"2022","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00508-016-1109-3","article-title":"Venovenous extracorporeal membrane oxygenation for ARDS: Outcome analysis of a Croatian referral center for respiratory ECMO","volume":"129","author":"Novokmet","year":"2017","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/03913988231163891","article-title":"Extracorporeal membrane oxygenation in COVID-19: Results of the Croatian extracorporeal membrane oxygenation referral center","volume":"46","author":"Santini","year":"2023","journal-title":"Int. J. Artif. Organs"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/00003495-199754060-00008","article-title":"Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia","volume":"54","author":"Wilde","year":"1997","journal-title":"Drugs"},{"key":"ref_82","first-page":"731","article-title":"Laboratory diagnosis of heparin-induced thrombocytopenia and monitoring of alternative anticoagulants","volume":"10","author":"Leo","year":"2003","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/bjh.12059","article-title":"Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: Second edition","volume":"159","author":"Watson","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1213\/ane.0b013e31816794d9","article-title":"Extracorporeal membrane oxygenation with danaparoid sodium after massive pulmonary embolism","volume":"106","author":"Bauer","year":"2008","journal-title":"Anesth. Analg."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.athoracsur.2019.08.040","article-title":"Venoarterial-extracorporeal membrane oxygenation without routine systemic anticoagulation decreases adverse events","volume":"109","author":"Wood","year":"2020","journal-title":"Ann. Thorac. Surg."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4068\/cmj.2017.53.2.110","article-title":"Anticoagulation therapy during extracorporeal membrane oxygenator support in pediatric patients","volume":"53","author":"Cho","year":"2017","journal-title":"Chonnam Med. J."},{"key":"ref_87","unstructured":"Extracorporeal Life Support Organization (2025, September 29). ELSO Anticoagulation Guideline. Available online: https:\/\/www.elso.org\/ecmo-resources\/elso-ecmo-guidelines.aspx."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Nakamura, M., Imamura, T., Hida, Y., Izumida, T., Nakagaito, M., Nagura, S., Doi, T., and Kinugawa, K. (2025). Anticoagulation with nafamostat mesilate during impella support: A case report. Medicina, 61.","DOI":"10.3390\/medicina61020309"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1111\/aor.14276","article-title":"Use of nafamostat mesilate for anticoagulation during extracorporeal membrane oxygenation: A systematic review","volume":"46","author":"Sanfilippo","year":"2022","journal-title":"Artif. Organs"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4266\/acc.2021.01312","article-title":"The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation","volume":"37","author":"Lee","year":"2022","journal-title":"Acute Crit. Care"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.athoracsur.2016.01.044","article-title":"Anticoagulation during extracorporeal membrane oxygenation; nafamostat mesilate versus heparin","volume":"102","author":"Lim","year":"2016","journal-title":"Ann. Thorac. Surg."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1051\/ject\/2002342144","article-title":"Nitric oxide: Platelet protectant properties during cardiopulmonary bypass\/ECMO","volume":"34","author":"Jacobson","year":"2002","journal-title":"J. Extra-Corpor. Technol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-0043-1761488","article-title":"The History of Extracorporeal Membrane Oxygenation and the Development of Extracorporeal Membrane Oxygenation Anticoagulation","volume":"50","author":"Bartlett","year":"2024","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Obstals, F., Vorobii, M., Riedel, T., de los Santos Pereira, A., Bruns, M., Singh, S., and Rodriguez-Emmenegger, C. (2018). Improving hemocompatibility of membranes for extracorporeal membrane oxygenators by grafting nonthrombogenic polymer brushes. Macromol. Biosci., 18.","DOI":"10.1002\/mabi.201700359"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1021\/acsbiomaterials.1c00758","article-title":"Anti-thrombogenic surface coatings for extracorporeal membrane oxygenation: A narrative review","volume":"7","author":"Zhang","year":"2021","journal-title":"ACS Biomater. Sci. Eng."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/10731198309118804","article-title":"A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue","volume":"11","author":"Larm","year":"1983","journal-title":"Biomater. Med. Devices Artif. Organs"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/0267659109106773","article-title":"Bioline heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia: The immune reaction appeared to continue unabated","volume":"24","author":"Pappalardo","year":"2009","journal-title":"Perfusion"},{"key":"ref_98","first-page":"6624682","article-title":"Can heparin-coated ECMO cannulas induce thrombocytopenia in COVID-19 patients?","volume":"2021","author":"Steinlechner","year":"2021","journal-title":"Case Rep. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1067\/mtc.2001.111655","article-title":"Heparin antibodies and thromboembolism in heparin-coated and noncoated ventricular assist devices","volume":"121","author":"Koster","year":"2001","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_100","unstructured":"Laurance Lequier, G.A., Omar Al-Ibrahim, M.B., Dan Brodie, T.B., Shannon Buckvold, L.C., Steve Conrad, D.C., Heidi Dalton, J.F., Bill Harris, R.M., Paden, M., Natalie Rintoul, L.R., and Phil Spinella, J.T. (2014). ELSO Anticoagulation Guideline, ELSO."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12959-022-00401-2","article-title":"Evaluation of clinical outcomes in patients treated with heparin or direct thrombin inhibitors during extracorporeal membrane oxygenation: A systematic review and meta-analysis","volume":"20","author":"Roth","year":"2022","journal-title":"Thromb. J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/MAT.0000000000001230","article-title":"Thrombosis and bleeding in extracorporeal membrane oxygenation (ECMO) without anticoagulation: A systematic review","volume":"67","author":"Olson","year":"2021","journal-title":"ASAIO J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.21037\/jtd.2020.04.54","article-title":"Extracorporeal membrane oxygenation without systemic anticoagulation: A case-series in challenging conditions","volume":"12","author":"Fina","year":"2020","journal-title":"J. Thorac. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"De Paulis, S., and Cavaliere, F. (2022). Anticoagulation management in high bleeding-risk ECMO in adults. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.884063"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.athoracsur.2020.02.011","article-title":"Feasibility of venovenous extracorporeal membrane oxygenation without systemic anticoagulation","volume":"110","author":"Kurihara","year":"2020","journal-title":"Ann. Thorac. Surg."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/11\/2705\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:44:13Z","timestamp":1762915453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/11\/2705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":105,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["biomedicines13112705"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13112705","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]}}}